Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neumora Therapeutics, Inc.NMRA · Entity 6115 | Director · President & CEO | August 20, 2026 | August 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neumora Therapeutics, Inc.
Report date August 20, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.52 · Expires 2036-08-20 | Direct | 500,000 |
Reported balance
After 2026-08-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-20 · Grant · Acquired 500,000 · Balance 500,000 F1: 25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Metsera, Inc.
Report date November 13, 2025 · Filed November 13, 2025
Section 16 reporting ended · disclosed 2025-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-11-13 transaction · row 1
1 source rowRow 1 · 2025-11-13 · Disposition to issuer · Disposed 2,688 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, F2: (Continued from footnote 1) without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration"). F5: On November 12, 2025, the Reporting Person was granted restricted stock units ("RSUs") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in 36 substantially equal monthly installments from November 12, 2025. Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. The cash payment and the CVRs are not subject to vesting. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,688 |
Reported balance
After 2025-11-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-11-13 · Grant · Acquired 2,688 · Balance 2,688 F5: On November 12, 2025, the Reporting Person was granted restricted stock units ("RSUs") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in 36 substantially equal monthly installments from November 12, 2025. Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. The cash payment and the CVRs are not subject to vesting. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.25 · Expires 2035-05-19 | Direct | 0 |
Reported balance
After 2025-11-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-11-13 · Disposition to issuer · Disposed 16,125 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, F4: (Continued from footnote 3) the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options, except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger. F6: This option provided for vesting in 12 substantially equal monthly installments from May 20, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.33 · Expires 2034-09-26 | IndirectBy LLC | 0 |
Reported balance
After 2025-11-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-11-13 · Disposition to issuer · Disposed 148,953 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, F4: (Continued from footnote 3) the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options, except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger. F7: This option provided for vesting in 36 substantially equal monthly installments from September 27, 2024. F8: Reflects securities held by Maple DE Holdings LLC (the "LLC"). The units of the LLC are held by a trust for which the Reporting Person exercises investment control and is a beneficiary. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash,
F2: (Continued from footnote 1) without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration").
F3: Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options,
F4: (Continued from footnote 3) the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options, except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger.
F5: On November 12, 2025, the Reporting Person was granted restricted stock units ("RSUs") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in 36 substantially equal monthly installments from November 12, 2025. Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. The cash payment and the CVRs are not subject to vesting.
F6: This option provided for vesting in 12 substantially equal monthly installments from May 20, 2025.
F7: This option provided for vesting in 36 substantially equal monthly installments from September 27, 2024.
F8: Reflects securities held by Maple DE Holdings LLC (the "LLC"). The units of the LLC are held by a trust for which the Reporting Person exercises investment control and is a beneficiary.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 20, 2026 Filed Aug 21, 2026 23:06 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0001610717-26-000381 · form4.xml · derivative · entry 1 Pinto Joshua · CIK 0001992595 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2036-08-20 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 22:06 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | SaleCommon Stock | 5,967 | $3.54 | $21,093.35 |
DisclosureSEC source: 0001610717-26-000053 · form4.xml · nonDerivative · entry 1 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,783 F1 · kind: The shares were sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| January 08, 2026 Filed Jan 9, 2026 21:18 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 1,200,000 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001610717-26-000009 · form4.xml · derivative · entry 1 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,200,000 Underlying: Common Stock · 1,200,000 shares Expires 2036-01-08 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 8, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| November 13, 2025 Filed Nov 13, 2025 21:00 UTC | Metsera, Inc. MTSR · Entity 73102 | Disposition to issuerStock Option (right to buy) · Derivative | 148,953 | Not disclosed Strike: $4.33 | Not disclosed |
DisclosureSEC source: 0001193125-25-280799 · ownership.xml · derivative · entry 4 Pinto Joshua · CIK 0001992595 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By LLC Disclosed balance after: 0 Underlying: Common Stock · 148,953 shares Expires 2034-09-26 F3 · security: Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, F4 · security: (Continued from footnote 3) the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options, except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger. F3 · price: Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, F4 · price: (Continued from footnote 3) the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options, except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger. F7 · derivative.exercise_date: This option provided for vesting in 36 substantially equal monthly installments from September 27, 2024. F8 · ownership.nature: Reflects securities held by Maple DE Holdings LLC (the "LLC"). The units of the LLC are held by a trust for which the Reporting Person exercises investment control and is a beneficiary. Read SEC document |
| November 13, 2025 Filed Nov 13, 2025 21:00 UTC | Metsera, Inc. MTSR · Entity 73102 | Disposition to issuerStock Option (right to buy) · Derivative | 16,125 | Not disclosed Strike: $29.25 | Not disclosed |
DisclosureSEC source: 0001193125-25-280799 · ownership.xml · derivative · entry 3 Pinto Joshua · CIK 0001992595 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,125 shares Expires 2035-05-19 F3 · security: Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, F4 · security: (Continued from footnote 3) the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options, except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger. F3 · price: Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, F4 · price: (Continued from footnote 3) the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options, except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger. F6 · derivative.exercise_date: This option provided for vesting in 12 substantially equal monthly installments from May 20, 2025. Read SEC document |
| November 13, 2025 Filed Nov 13, 2025 21:00 UTC | Metsera, Inc. MTSR · Entity 73102 | GrantRestricted Stock Unit · Derivative | 2,688 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001193125-25-280799 · ownership.xml · derivative · entry 2 Pinto Joshua · CIK 0001992595 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,688 Underlying: Common Stock · 2,688 shares Expires not disclosed F5 · price: On November 12, 2025, the Reporting Person was granted restricted stock units ("RSUs") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in 36 substantially equal monthly installments from November 12, 2025. Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. The cash payment and the CVRs are not subject to vesting. F5 · derivative.exercise_date: On November 12, 2025, the Reporting Person was granted restricted stock units ("RSUs") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in 36 substantially equal monthly installments from November 12, 2025. Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. The cash payment and the CVRs are not subject to vesting. F5 · derivative.expiration_date: On November 12, 2025, the Reporting Person was granted restricted stock units ("RSUs") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in 36 substantially equal monthly installments from November 12, 2025. Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. The cash payment and the CVRs are not subject to vesting. Read SEC document |
| November 13, 2025 Filed Nov 13, 2025 21:00 UTC | Metsera, Inc. MTSR · Entity 73102 | Disposition to issuerCommon Stock | 2,688 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-280799 · ownership.xml · nonDerivative · entry 1 Pinto Joshua · CIK 0001992595 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, F2 · kind: (Continued from footnote 1) without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration"). F1 · price: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, F2 · price: (Continued from footnote 1) without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration"). F5 · price: On November 12, 2025, the Reporting Person was granted restricted stock units ("RSUs") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in 36 substantially equal monthly installments from November 12, 2025. Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. The cash payment and the CVRs are not subject to vesting. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:25 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 3,000,000 | Not disclosed Strike: $0.72 | Not disclosed |
DisclosureSEC source: 0000950170-25-079908 · ownership.xml · derivative · entry 14 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000,000 Underlying: Common Stock · 3,000,000 shares Expires 2035-02-13 F9 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F8 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:25 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 170,000 | Not disclosed Strike: $0.72 | Not disclosed |
DisclosureSEC source: 0000950170-25-079908 · ownership.xml · derivative · entry 13 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2034-02-14 F9 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F7 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:25 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 127,448 | Not disclosed Strike: $0.72 | Not disclosed |
DisclosureSEC source: 0000950170-25-079908 · ownership.xml · derivative · entry 12 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,448 Underlying: Common Stock · 127,448 shares Expires 2033-06-23 F9 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F6 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the "Vesting Commencement Date'), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:25 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 720,084 | Not disclosed Strike: $0.72 | Not disclosed |
DisclosureSEC source: 0000950170-25-079908 · ownership.xml · derivative · entry 11 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 720,084 Underlying: Common Stock · 720,084 shares Expires 2032-01-27 F9 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F5 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:25 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 223,034 | Not disclosed Strike: $0.72 | Not disclosed |
DisclosureSEC source: 0000950170-25-079908 · ownership.xml · derivative · entry 10 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,034 Underlying: Common Stock · 223,034 shares Expires 2031-06-07 F9 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F4 · derivative.exercise_date: The performance-based stock option becomes exercisable in two tranches upon the achievement of specified stock price milestones. Each tranche shall vest in 24 equal monthly installments measured from the stock price achievement date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:25 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 270,828 | Not disclosed Strike: $0.72 | Not disclosed |
DisclosureSEC source: 0000950170-25-079908 · ownership.xml · derivative · entry 9 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 270,828 Underlying: Common Stock · 270,828 shares Expires 2031-06-07 F9 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F3 · derivative.exercise_date: The option is early exercisable. 1/36th of the shares subject to the option vest on each monthly anniversary measured from June 1, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested on the third anniversary of the Vesting Commencement Date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:25 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 223,034 | Not disclosed Strike: $0.72 | Not disclosed |
DisclosureSEC source: 0000950170-25-079908 · ownership.xml · derivative · entry 8 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,034 Underlying: Common Stock · 223,034 shares Expires 2031-06-07 F9 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from June 30, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:25 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,000,000 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-079908 · ownership.xml · derivative · entry 7 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000,000 shares Expires 2035-02-13 F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F8 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:25 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 170,000 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-079908 · ownership.xml · derivative · entry 6 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 170,000 shares Expires 2034-02-14 F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F7 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:25 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 127,448 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-079908 · ownership.xml · derivative · entry 5 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 127,448 shares Expires 2033-06-23 F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F6 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the "Vesting Commencement Date'), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:25 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 720,084 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-079908 · ownership.xml · derivative · entry 4 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 720,084 shares Expires 2032-01-27 F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F5 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:25 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 223,034 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-079908 · ownership.xml · derivative · entry 3 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 223,034 shares Expires 2031-06-07 F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F4 · derivative.exercise_date: The performance-based stock option becomes exercisable in two tranches upon the achievement of specified stock price milestones. Each tranche shall vest in 24 equal monthly installments measured from the stock price achievement date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:25 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 270,828 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-079908 · ownership.xml · derivative · entry 2 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 270,828 shares Expires 2031-06-07 F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F3 · derivative.exercise_date: The option is early exercisable. 1/36th of the shares subject to the option vest on each monthly anniversary measured from June 1, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested on the third anniversary of the Vesting Commencement Date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:25 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 223,034 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-079908 · ownership.xml · derivative · entry 1 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 223,034 shares Expires 2031-06-07 F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from June 30, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. Read SEC document |
| May 22, 2025 Filed May 22, 2025 19:42 UTC | Metsera, Inc. MTSR · Entity 73102 | GiftStock Option (Right to Buy) · Derivative | 148,953 | $0.00 Strike: $4.33 | $0.00 |
DisclosureSEC source: 0000950170-25-076583 · ownership.xml · derivative · entry 3 Pinto Joshua · CIK 0001992595 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By LLC Disclosed balance after: 148,953 Underlying: Common Stock · 148,953 shares Expires 2034-09-26 F2 · kind: Reflects securities transferred by the Reporting Person to Maple DE Holdings LLC (the "LLC"). The units of the LLC are held by a trust for which the Reporting Person exercises investment control and is a beneficiary. F3 · derivative.exercise_date: The options were granted on September 27, 2024. The options vest and become exercisable in 36 substantially equal monthly installments following the grant date. F2 · ownership.nature: Reflects securities transferred by the Reporting Person to Maple DE Holdings LLC (the "LLC"). The units of the LLC are held by a trust for which the Reporting Person exercises investment control and is a beneficiary. Read SEC document |
| May 22, 2025 Filed May 22, 2025 19:42 UTC | Metsera, Inc. MTSR · Entity 73102 | GiftStock Option (Right to Buy) · Derivative | 148,953 | $0.00 Strike: $4.33 | $0.00 |
DisclosureSEC source: 0000950170-25-076583 · ownership.xml · derivative · entry 2 Pinto Joshua · CIK 0001992595 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 148,953 shares Expires 2034-09-26 F2 · kind: Reflects securities transferred by the Reporting Person to Maple DE Holdings LLC (the "LLC"). The units of the LLC are held by a trust for which the Reporting Person exercises investment control and is a beneficiary. F3 · derivative.exercise_date: The options were granted on September 27, 2024. The options vest and become exercisable in 36 substantially equal monthly installments following the grant date. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:42 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GiftCommon Stock | 13,202 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000128 · form4.xml · nonDerivative · entry 2 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 152,167 F2 · ownership.nature: Shares held by Maple DE Holdings LLC, which is the entity defined above as "Family LLC". Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:42 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GiftCommon Stock | 13,202 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000128 · form4.xml · nonDerivative · entry 1 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,750 F1 · kind: On May 21 2025, the Reporting Person transferred 13,202 shares of Common Stock to a family limited liability company (the "Family LLC") in a transaction exempt from reporting pursuant to Rule 16a-13. The Reporting Person continues to exercise investment control over the Common Stock held by the Family LLC. Read SEC document |
| May 20, 2025 Filed May 22, 2025 19:42 UTC | Metsera, Inc. MTSR · Entity 73102 | GrantStock Option (Right to Buy) · Derivative | 16,125 | $0.00 Strike: $29.25 | $0.00 |
DisclosureSEC source: 0000950170-25-076583 · ownership.xml · derivative · entry 1 Pinto Joshua · CIK 0001992595 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,125 Underlying: Common Stock · 16,125 shares Expires 2035-05-19 F1 · derivative.exercise_date: The options will vest and become exercisable in 12 substantially equal monthly installments after the date of grant, such that the option will be vested in full on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:11 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | SaleCommon Stock | 8,048 | $1.67 | $13,477.18 |
DisclosureSEC source: 0001610717-25-000027 · form4.xml · nonDerivative · entry 1 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,952 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on April 18, 2024 and subsequently amended on May 22, 2024, which provides for the automatic sale of shares of common stock that would otherwise be issuable on each vesting date of a covered restricted stock unit in an amount necessary to satisfy the applicable withholding obligation. F2 · price: This transaction was executed in multiple trades in prices ranging from $1.66 to $1.6995, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 170,000 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-022319 · ownership.xml · derivative · entry 13 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2034-02-14 F9 · derivative.exercise_price: Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F8 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 127,448 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-022319 · ownership.xml · derivative · entry 12 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,448 Underlying: Common Stock · 127,448 shares Expires 2033-06-23 F9 · derivative.exercise_price: Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F7 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the "Vesting Commencement Date'), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 720,084 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-022319 · ownership.xml · derivative · entry 11 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 720,084 Underlying: Common Stock · 720,084 shares Expires 2032-01-27 F9 · derivative.exercise_price: Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F6 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 223,034 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-022319 · ownership.xml · derivative · entry 10 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,034 Underlying: Common Stock · 223,034 shares Expires 2031-06-07 F9 · derivative.exercise_price: Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F5 · derivative.exercise_date: The performance-based stock option becomes exercisable in two tranches upon the achievement of specified stock price milestones. Each tranche shall vest in 24 equal monthly installments measured from the stock price achievement date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 270,828 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-022319 · ownership.xml · derivative · entry 9 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 270,828 Underlying: Common Stock · 270,828 shares Expires 2031-06-07 F9 · derivative.exercise_price: Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F4 · derivative.exercise_date: The option is early exercisable. 1/36th of the shares subject to the option vest on each monthly anniversary measured from June 1, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested on the third anniversary of the Vesting Commencement Date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 223,034 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-022319 · ownership.xml · derivative · entry 8 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,034 Underlying: Common Stock · 223,034 shares Expires 2031-06-07 F9 · derivative.exercise_price: Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F2 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from June 30, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 170,000 | Not disclosed Strike: $18.07 | Not disclosed |
DisclosureSEC source: 0000950170-25-022319 · ownership.xml · derivative · entry 7 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 170,000 shares Expires 2034-02-14 F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F8 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 127,448 | Not disclosed Strike: $6.36 | Not disclosed |
DisclosureSEC source: 0000950170-25-022319 · ownership.xml · derivative · entry 6 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 127,448 shares Expires 2033-06-23 F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F7 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the "Vesting Commencement Date'), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 720,084 | Not disclosed Strike: $4.63 | Not disclosed |
DisclosureSEC source: 0000950170-25-022319 · ownership.xml · derivative · entry 5 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 720,084 shares Expires 2032-01-27 F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F6 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 223,034 | Not disclosed Strike: $2.51 | Not disclosed |
DisclosureSEC source: 0000950170-25-022319 · ownership.xml · derivative · entry 4 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 223,034 shares Expires 2031-06-07 F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F5 · derivative.exercise_date: The performance-based stock option becomes exercisable in two tranches upon the achievement of specified stock price milestones. Each tranche shall vest in 24 equal monthly installments measured from the stock price achievement date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 270,828 | Not disclosed Strike: $2.51 | Not disclosed |
DisclosureSEC source: 0000950170-25-022319 · ownership.xml · derivative · entry 3 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 270,828 shares Expires 2031-06-07 F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F4 · derivative.exercise_date: The option is early exercisable. 1/36th of the shares subject to the option vest on each monthly anniversary measured from June 1, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested on the third anniversary of the Vesting Commencement Date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 223,034 | Not disclosed Strike: $2.51 | Not disclosed |
DisclosureSEC source: 0000950170-25-022319 · ownership.xml · derivative · entry 2 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 223,034 shares Expires 2031-06-07 F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F2 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from June 30, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 3,000,000 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0000950170-25-022319 · ownership.xml · derivative · entry 1 Pinto Joshua · CIK 0001992595 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000,000 Underlying: Common Stock · 3,000,000 shares Expires 2035-02-13 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| August 27, 2024 Filed Aug 27, 2024 21:58 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | SaleCommon Stock | 15,693 | $11.39 | $178,806.04 |
DisclosureSEC source: 0001610717-24-000457 · form4.xml · nonDerivative · entry 1 Pinto Joshua · CIK 0001992595 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 138,965 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on April 18, 2024 and subsequently amended on May 22, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $11.1572 to $11.58, inclusive. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Shares held by Maple DE Holdings LLC. Read SEC document |
| August 26, 2024 Filed Aug 26, 2024 22:17 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | SaleCommon Stock | 31,642 | $11.78 | $372,587.71 |
DisclosureSEC source: 0001610717-24-000456 · form4.xml · nonDerivative · entry 3 Pinto Joshua · CIK 0001992595 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 154,658 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on April 18, 2024 and subsequently amended on May 22, 2024. F5 · price: This transaction was executed in multiple trades at prices ranging from $11.61 to $11.98, inclusive. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Shares held by Maple DE Holdings LLC. Read SEC document |
| August 23, 2024 Filed Aug 26, 2024 22:17 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | SaleCommon Stock | 24,169 | $11.59 | $280,005.12 |
DisclosureSEC source: 0001610717-24-000456 · form4.xml · nonDerivative · entry 2 Pinto Joshua · CIK 0001992595 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 186,300 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on April 18, 2024 and subsequently amended on May 22, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $11.40 to $11.74, inclusive. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Shares held by Maple DE Holdings LLC. Read SEC document |
| August 22, 2024 Filed Aug 26, 2024 22:17 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | SaleCommon Stock | 28,496 | $11.63 | $331,468.32 |
DisclosureSEC source: 0001610717-24-000456 · form4.xml · nonDerivative · entry 1 Pinto Joshua · CIK 0001992595 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 210,469 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on April 18, 2024 and subsequently amended on May 22, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $11.43 to $12.06, inclusive. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Shares held by Maple DE Holdings LLC. Read SEC document |
| April 17, 2024 Filed Jun 29, 2024 01:00 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GiftCommon Stock | 238,965 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000380 · form4.xml · nonDerivative · entry 1 Pinto Joshua · CIK 0001992595 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 238,965 F1 · kind: On April 8, 2024, the Reporting Person transferred 238,965 shares of Common Stock to a family limited liability company (the "Family LLC") in a transaction exempt from reporting pursuant to Rule 16a-13. The transaction reported herein reflects the transfer for no consideration of membership interests in the Family LLC to a trust of which the Reporting Person is a beneficiary for estate planning purposes. The Reporting Person continues to exercise investment control over the Common Stock held by the Family LLC. F2 · ownership.nature: Shares held by Maple DE Holdings LLC, which is the entity defined above as "Family LLC". Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:21 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 170,000 | $0.00 Strike: $18.07 | $0.00 |
DisclosureSEC source: 0001610717-24-000069 · form4.xml · derivative · entry 2 Pinto Joshua · CIK 0001992595 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2034-02-13 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:21 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantCommon Stock | 85,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000069 · form4.xml · nonDerivative · entry 1 Pinto Joshua · CIK 0001992595 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 323,965 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually measured from February 14, 2024 (the "Vesting Commencement Date"), such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.